Engineering of living autologous human umbilical cord cell-based septal occluder membranes using composite PGA-P4HB matrices

Biomaterials

Volumn 32, Issue 36, 2011, Pages 9630-9641

  Weber, Benedikt ^a,b   Schoenauer, Roman ^a,b   Papadopulos, Francesca ^b,c   Modregger, Peter ^d,e   Peter, Silvia ^d,f   Stampanoni, Marco ^d,f   Mauri, Arabella ^f   Mazza, Edoardo ^f,g   Gorelik, Julia ^h   Agarkova, Irina ^a,b   Frese, Laura ^a,b   Breymann, Christian ^b   Kretschmar, Oliver ⁱ   Hoerstrup, Simon P ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d PAUL SCHERRER INSTITUTE   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f ETH ZURICH   (Switzerland)

^g SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Biodegradable matrix; Crimping; Poly 4 hydroxybutyrate; Polyglycolic acid; Septal occluder system; Umbilical cord cells

Indexed keywords

CRIMPING; MATRIX; OCCLUDER; POLY-4-HYDROXYBUTYRATE; POLYGLYCOLIC ACID; UMBILICAL CORDS;

DEFECTS; SCANNING ELECTRON MICROSCOPY; TENSILE TESTING; TISSUE;

COMPOSITE MEMBRANES;

4 HYDROXYBUTYRIC ACID; POLY 4 HYDROXYBUTYRATE; POLYGLYCOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL STRUCTURE; CELL VIABILITY; COMPOSITE MATERIAL; CONGENITAL HEART MALFORMATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; IN VITRO STUDY; INTERFEROMETRY; MICROTECHNOLOGY; PHENOTYPE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SEPTAL OCCLUDER; TISSUE ENGINEERED OCCLUDER MEMBRANE; TISSUE ENGINEERING; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BIOENGINEERING; BIOMECHANICS; CELL SEPARATION; CELL SHAPE; EXTRACELLULAR MATRIX; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFEROMETRY; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MICROSCOPY, ELECTRON, SCANNING; PHENOTYPE; POLYESTERS; POLYGLYCOLIC ACID; SEPTAL OCCLUDER DEVICE; SUS SCROFA; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TISSUE SURVIVAL; UMBILICAL CORD; WHARTON JELLY;

SUS;

EID: 80054061779     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.070     Document Type: Article

References (46)

1. Piéchaud J.F. Closing down: transcatheter closure of intracardiac defects and vessel embolisations. Heart 2004, 90(12):1505-1510.
2. Moake L., Ramaciotti C. Atrial septal defect treatment options. AACN Clin Issues 2005, 16(2):252-266.
3. Jux C., Bertram H., Wohlsein P., Brügmann M., Wüboldt P., Fink C., et al. Experimental ASD closure using autologous cell-seeded interventional closure devices. Cardiovasc Res 2002, 53(1):181-191.
4. Kharouf R., Luxenberg D.M., Khalid O., Abdulla R. Atrial septal defect: spectrum of care. Pediatr Cardiol 2008, 29(2):271-280.
5. Van den Branden B.J., Post M.C., Plokker H.W., ten Berg J.M., Suttorp M.J. Patent foramen ovale closure using a bioabsorbable closure device: safety and efficacy at 6-month follow-up. JACC Cardiovasc Interv 2010, 3(9):968-973.
6. Duong-Hong D., Tang Y.D., Wu W., Venkatraman S.S., Boey F., Lim J., et al. Fully biodegradable septal defect occluders - a double umbrella design. Catheter Cardiovasc Interv 2010, 76(5):711-718.
7. Weber B., Emmert M.Y., Schoenauer R., Brokopp C., Baumgartner L., Hoerstrup S.P. Tissue engineering on matrix: future of autologous tissue replacement. Semin Immunopathol 2011, 33(3):307-315.
8. Schmidt D., Stock U.A., Hoerstrup S.P. Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices. Philos Trans R Soc Lond B Biol Sci 2007, 362(1484):1505-1512.
9. Mol A., Rutten M.C., Driessen N.J., Bouten C.V., Zünd G., Baaijens F.P., et al. Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation 2006, 114(1):I152-I158.
10. Mol A., Smits A.I., Bouten C.V., Baaijens F.P. Tissue engineering of heart valves: advances and current challenges. Expert Rev Med Devices 2009, 6(3):259-275.
11. Mol A., Driessen N.J., Rutten M.C., Hoerstrup S.P., Bouten C.V., Baaijens F.P. Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann Biomed Eng 2005, 33(12):1778-1788.
12. Driessen N.J., Mol A., Bouten C.V., Baaijens F.P. Modeling the mechanics of tissue-engineered human heart valve leaflets. J Biomech 2007, 40(2):325-334.
13. Hoerstrup S.P., Cummings I., Lachat M., Schoen F.J., Jenni R., Leschka S., et al. Functional growth in tissue-engineered living, vascular grafts: follow-up at 100 weeks in a large animal model. Circulation 2006, 114(1):I159-I166.
14. Roh J.D., Sawh-Martinez R., Brennan M.P., Jay S.M., Devine L., Rao D.A., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A 2010, 107(10):4669-4674.
15. Naito Y., Shinoka T., Duncan D., Hibino N., Solomon D., Cleary M., et al. Vascular tissue engineering: towards the next generation vascular grafts. Adv Drug Deliv Rev 2011, 63(5):312-323.
16. Schmidt D., Dijkman P.E., Driessen-Mol A., Stenger R., Mariani C., Puolakka A., et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010, 56(6):510-520.
17. Weber B., Scherman J., Emmert M.Y., Gruenenfelder J., Verbeek R., Bracher M., et al. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J 2011, [Epub ahead of print].
18. Shinoka T., Breuer C. Tissue-engineered blood vessels in pediatric cardiac surgery. Yale J Biol Med 2008, 81(4):161-166.
19. Hibino N., McGillicuddy E., Matsumura G., Ichihara Y., Naito Y., Breuer C., et al. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg 2010, 139(2):431-436.
20. Schmidt D., Mol A., Breymann C., Achermann J., Odermatt B., Gössi M. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation 2006, 114(1):I125-I131.
21. Schmidt D., Achermann J., Odermatt B., Breymann C., Mol A., Genoni M., et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation 2007, 116(11):I64-I70.
22. Schmidt D., Achermann J., Odermatt B., Genoni M., Zund G., Hoerstrup S.P. Cryopreserved amniotic fluid-derived cells: a lifelong autologous fetal stem cell source for heart valve tissue engineering. J Heart Valve Dis 2008, 17(4):446-455.
23. Schmidt D., Breymann C., Weber A., Guenter C.I., Neuenschwander S., Zund G., et al. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg 2004, 78(6):2094-2098.
24. Schmidt D., Mol A., Neuenschwander S., Breymann C., Gössi M., Zund G., et al. Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur J Cardiothorac Surg 2005, 27(5):795-800.
25. Schmidt D., Asmis L.M., Odermatt B., Kelm J., Breymann C., Gössi M., et al. Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann Thorac Surg 2006, 82(4):1465-1471.
26. Schmidt D., Mol A., Odermatt B., Neuenschwander S., Breymann C., Gössi M., et al. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng 2006, 12(11):3223-3232.
27. Weber B., Zeisberger S.M., Hoerstrup S.P. Prenatally harvested cells for cardiovascular tissue engineering: fabrication of autologous implants prior to birth. Placenta 2011, [Epub ahead of print].
28. Mol A., van Lieshout M.I., Dam-de Veen C.G., Neuenschwander S., Hoerstrup S.P., Baaijens F.P., et al. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials 2005, 26:3113-3121.
29. McDonald S.A., Marone F., Hintermüller C., Mikuljan G., David C., Pfeiffer F., et al. Advanced phase-contrast imaging using a grating interferometer. J Synchrotron Radiat 2009, 16(4):562-572.
30. Suleski T.J. Generation of Lohmann images from binary-phase Talbot array illuminators. Appl Opt 1997, 36:4686-4691.
31. Weitkamp T., Diaz A., David C., Pfeiffer F., Stampanoni M., Cloetens P., et al. X-ray phase imaging with a grating interferometer. Opt Express 2005, 13(16):6296-6304.
32. Cesarone C.F., Bolognesi C., Santi L. Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal Biochem 1979, 100(1):188-197.
33. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986, 883(2):173-177.
34. Huszar G., Maiocco J., Naftolin F. Monitoring of collagen and collagen fragments in chromatography of protein mixtures. Anal Biochem 1980, 105:424-429.
35. Novak P., Li C., Shevchuk A.I., Stepanyan R., Caldwell M., Hughes S., et al. Nanoscale live cell imaging using hopping probe ion conductance microscopy. Nat Methods 2009, 6(4):279-281.
36. Shevchuk A.I., Novak P., Takahashi Y., Clarke R., Miragoli M., Babakinejad B., et al. Realizing the biological and biomedical potential of nanoscale imaging using a pipette probe. Nanomedicine (Lond) 2011, 6(3):565-575.
37. Hoffman J.I., Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002, 39(12):1890-1900.
38. Sideris B., Sideris E., Calachanis M., Papantoniou V., Moulopoulos S. The immediate release patch in the correction of experimental atrial septal defects. Catheter Cardiovasc Interv 2010, 76(4):572-577.
39. Weber B., Hoerstrup S.P. Regenerating heart valves. Regenerating the heart: stem cells and the cardiovascular system 2011, 403-442. Springer, [Chapter 29]. I.S. Cohen, G.R. Gaudette (Eds.).
40. Klouda L., Vaz C.M., Mol A., Baaijens F.P., Bouten C.V. Effect of biomimetic conditions on mechanical and structural integrity of PGA/P4HB and electrospun PCL scaffolds. J Mater Sci Mater Med 2008, 19(3):1137-1144.
41. Balguid A., Mol A., van Marion M.H., Bank R.A., Bouten C.V., Baaijens F.P. Tailoring fiber diameter in electrospun poly(epsilon-caprolactone) scaffolds for optimal cellular infiltration in cardiovascular tissue engineering. Tissue Eng Part A 2009, 15(2):437-444.
42. Jux C., Bertram H., Wohlsein P., Bruegmann M., Paul T. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol 2006, 48(1):161-169.
43. Mullen M.J., Hildick-Smith D., De Giovanni J.V., Duke C., Hillis W.S., Morrison W.L., et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006, 114(18):1962-1967.
44. Sigler M., Jux C. Biocompatibility of septal defect closure devices. Heart 2007, 93(4):444-449.
45. Morgan G., Lee K.J., Chaturvedi R., Benson L. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv 2010, 76(2):241-245.
46. Jux C., Bertram H., Wohlsein P., Bruegmann M., Fink C., Wueboldt P., et al. Experimental preseeding of the STARFlex atrial septal occluder device with autologous cells. J Interv Cardiol 2001, 14(3):309-312.